Syngene International Limited (NSE:SYNGENE)
720.20
+0.65 (0.09%)
Mar 28, 2025, 3:30 PM IST
Syngene International Revenue
Syngene International had revenue of 9.44B INR in the quarter ending December 31, 2024, with 10.57% growth. This brings the company's revenue in the last twelve months to 35.41B, down -0.70% year-over-year. In the fiscal year ending March 31, 2024, Syngene International had annual revenue of 34.89B with 9.26% growth.
Revenue (ttm)
35.41B
Revenue Growth
-0.70%
P/S Ratio
8.24
Revenue / Employee
5.44M
Employees
6,510
Market Cap
291.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
Mar 31, 2021 | 21.84B | 1.72B | 8.57% |
Mar 31, 2020 | 20.12B | 1.86B | 10.20% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Syngene International News
- 5 weeks ago - Syngene International shares down 2.50% after USFDA issues Form 483 with five observations - Business Upturn
- 5 weeks ago - Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential - Business Upturn
- 5 weeks ago - Macquarie initiates Outperform call on Syngene International, Suven Pharma, Divi’s Lab, Blue Jet Healthcare - Business Upturn
- 7 weeks ago - Syngene International appoints Peter Bains as the CEO Designate of the company - Business Upturn
- 2 months ago - Syngene International shares fall nearly 6% on weak FY25 guidance and demand recovery delay - Business Upturn
- 3 months ago - Syngene shares surge after 2% equity worth Rs 706 crore changes hands in block deal - Business Upturn
- 4 months ago - Syngene International’s market cap decreases by Rs 760 crore as shares drop 2.19% today – Know More - Business Upturn